Carla Treloar1, Jake Rance2. 1. Centre for Social Research in Health, The University of New South Wales, Australia. Electronic address: c.treloar@unsw.edu.au. 2. Centre for Social Research in Health, The University of New South Wales, Australia.
Abstract
BACKGROUND: Given the increasing burden of hepatitis C (HCV) related liver disease, innovative health care models are required to extend the reach of HCV care and treatment. Opioid substitution treatment (OST) clinics are places of high HCV prevalence. The OST clinic is a complex environment, quite distinct to other health care settings, with punitive regulations and practices, and a client population likely to be mistrustful of systems of authority. Nonetheless, trust is widely documented as essential to effective therapeutic encounters. This paper examines what is required to develop a trustworthy service in a place, the OST clinic, described by some critics as a site of "social control". METHODS: In-depth interviews were conducted with 57 clients and 19 staff from four NSW pilot clinics participating in the Australian ETHOS study. RESULTS: Interview data were examined using Hall's framework of trust, involving five principle domains: fidelity, competence, honest, confidentiality and global trust. 'Honesty' was found to be key to participants' establishing trust in the co-located service and its staff. However, the clinic site was also found to be a place of rationed trust, in which the themes of OST as "ruling peoples' lives" and the fear of repercussions resulting from perceived transgressions against clinic rules, threatened to over-ride or undermine the development of trust in HCV services. Client participants described trusting health workers "to a point". They expressed concerns about the fidelity of co-located HCV and OST services and described fears of "institutionalised lies" and breaches of confidentiality. Anxieties around the latter revealed a sense of "us and them" held by some clients, one in which health workers were perceived to "stick together" by putting their own interests before those of the clients. DISCUSSION: Although the co-location of HCV and opioid treatments makes intuitive policy sense, HCV health workers in the OST space may be seen as representatives of a deeply mistrusted system. For the effective development of a trustworthy HCV care service, policy and practice activities are required to engender trust through clearly articulated explanations of service boundaries and the promotion of "success stories" through trusted peer networks.
BACKGROUND: Given the increasing burden of hepatitis C (HCV) related liver disease, innovative health care models are required to extend the reach of HCV care and treatment. Opioid substitution treatment (OST) clinics are places of high HCV prevalence. The OST clinic is a complex environment, quite distinct to other health care settings, with punitive regulations and practices, and a client population likely to be mistrustful of systems of authority. Nonetheless, trust is widely documented as essential to effective therapeutic encounters. This paper examines what is required to develop a trustworthy service in a place, the OST clinic, described by some critics as a site of "social control". METHODS: In-depth interviews were conducted with 57 clients and 19 staff from four NSW pilot clinics participating in the Australian ETHOS study. RESULTS: Interview data were examined using Hall's framework of trust, involving five principle domains: fidelity, competence, honest, confidentiality and global trust. 'Honesty' was found to be key to participants' establishing trust in the co-located service and its staff. However, the clinic site was also found to be a place of rationed trust, in which the themes of OST as "ruling peoples' lives" and the fear of repercussions resulting from perceived transgressions against clinic rules, threatened to over-ride or undermine the development of trust in HCV services. Client participants described trusting health workers "to a point". They expressed concerns about the fidelity of co-located HCV and OST services and described fears of "institutionalised lies" and breaches of confidentiality. Anxieties around the latter revealed a sense of "us and them" held by some clients, one in which health workers were perceived to "stick together" by putting their own interests before those of the clients. DISCUSSION: Although the co-location of HCV and opioid treatments makes intuitive policy sense, HCV health workers in the OST space may be seen as representatives of a deeply mistrusted system. For the effective development of a trustworthy HCV care service, policy and practice activities are required to engender trust through clearly articulated explanations of service boundaries and the promotion of "success stories" through trusted peer networks.
Authors: Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi Journal: Drug Alcohol Depend Date: 2019-03-08 Impact factor: 4.492
Authors: Sonya A MacParland; Marc Bilodeau; Jason Grebely; Julie Bruneau; Curtis Cooper; Marina Klein; Selena Sagan; Norma Choucha; Louise Balfour; Frank Bialystok; Mel Krajden; Jennifer Raven; Eve Roberts; Rodney Russell; Michael Houghton; D Lorne Tyrrell; Jordan J Feld Journal: Can J Gastroenterol Hepatol Date: 2014-10
Authors: Andy Guise; Maureen Seguin; Gitau Mburu; Susie McLean; Pippa Grenfell; Zahed Islam; Sergii Filippovych; Happy Assan; Andrea Low; Peter Vickerman; Tim Rhodes Journal: AIDS Care Date: 2017-03-10
Authors: Jessica F Magidson; John A Joska; Kristen S Regenauer; Emily Satinsky; Lena S Andersen; C J Seitz-Brown; Christina P C Borba; Steven A Safren; Bronwyn Myers Journal: Int J Drug Policy Date: 2019-05-10
Authors: Dimitra Panagiotoglou; Emanuel Krebs; Jeong Eun Min; Michelle Olding; Keith Ahamad; Lianping Ti; Julio S G Montaner; Bohdan Nosyk Journal: Int J Drug Policy Date: 2017-06-01
Authors: Stephen P Connolly; Gordana Avramovic; Walter Cullen; Tina McHugh; Eileen O'Connor; Geoff Mc Combe; Des Crowley; Anna Marie Naughton; Aidan Horan; John S Lambert Journal: Ir J Med Sci Date: 2020-08-06 Impact factor: 1.568
Authors: Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore Journal: Int J Drug Policy Date: 2017-07-03